Moderna shares rose Thursday after it announced it’s developing a two-in-one vaccine booster shot that protects against both Covid-19 and the seasonal flu.
- Moderna’s new vaccine, which the company is calling mRNA-1073, combines its current Covid vaccine with a flu shot that’s also under development.
- The company’s stock rose after the announcement.
The new vaccine, which the company is calling mRNA-1073, combines Moderna’s current Covid vaccine with a flu shot that’s also under development, according to a press release. Shares of Moderna jumped by more than 5% after the announcement.
“Today we are announcing the first step in our novel respiratory vaccine program with the development of a single dose vaccine that combines a booster against COVID-19 and a booster against flu,” CEO Stephane Bancel said in a statement Thursday. “We are making progress on enrolling patients in our rare disease programs, and we are fully enrolled in our personalized cancer vaccine trial. We believe this is just the beginning of a new age of information-based medicines.”